Leidse hoogleraren vanaf 1575

Meindert Danhof

Geboren
1951-12-30 te Groningen, Nederland
Geslacht
Man

Promotie (1980)

Type examen
Promotie
Datum
1980-10-23
Plaats
Leiden
Proefschrift
Antipyrine metabolite profile as a tool in the assessment of the activity of different drug oxidising enzymes in man

Gewoon hoogleraar (1996)

Benoeming
Gewoon hoogleraar
Faculteit
Geneeskunde, Wiskunde en Natuurwetenschappen
Vakgebied
Farmacologie
Leeropdracht
Farmacologie
Datum benoeming
1996
Datum oratie
1997-04-11
Titel oratie
Farmacologie in spiegelbeeld

Publicaties

Wetenschappelijk
Vakpublicaties
  • Westerhout J., van den Berg D.J., Hartman R., Danhof M. & de Lange E.C. (2014), Prediction of methotrexate CNS distribution in different species - influence of disease conditions., European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2014(Jan 22): 0928-0987.
  • Cock R.F. de, Piana C., Krekels E.H.J., Danhof M., Allegaert K. & Knibbe C.A.J. (2011), The role of population PK-PD modelling in paediatric clinical research., European Journal of Clinical Pharmacology 67(Suppl 1): 5-16.
  • Krekels E.H.J., DeJongh J., Lingen R.A. van, Marel C.D. van der, Choonara I., Lynn A.M., Danhof M., Tibboel D. & Knibbe C.A.J. (2011), Predictive performance of a recently developed population pharmacokinetic model for morphine and its metabolites in new datasets of (preterm) neonates, infants and children., 50(1): 51-63.
  • Knibbe C.A.J., Krekels E.H.J. & Danhof M. (2011), Advances in paediatric pharmacokinetics., Expert opinion on drug metabolism & toxicology 7(1): 1-8.
  • Steeg T.J. van, Krekels E.H.J., Freijer J., Danhof M. & Lange E.C.M. de (2010), Effect of altered AGP plasma binding on heart rate changes by S(-)-propranolol in rats using mechanism-based estimations of in vivo receptor affinity (K(B,vivo))., Journal of Pharmaceutical Sciences 99(5): 2511-20.
  • Knibbe C.A.J., Krekels E.H.J., Anker J.N. van den, DeJongh J., Santen G.W., Dijk M. van, Simons S.H., Lingen R.A. van, Jacqz-Aigrain E.M., Danhof M. & Tibboel D. (2009), Morphine glucuronidation in preterm neonates, infants and children younger than 3 years., Clinical Pharmacokinetics 48(6): 371-85.
  • Steeg T.J. van, Boralli V.B., Krekels E.H.J., Slijkerman P., Freijer J., Danhof M. & Lange E.C.M. de (2009), Influence of plasma protein binding on pharmacodynamics: Estimation of in vivo receptor affinities of beta blockers using a new mechanism-based PK-PD modelling approach., Journal of Pharmaceutical Sciences 98(10): 3816-28.
  • Steeg T.J. van, Krekels E.H.J., Danhof M. & Lange E.C.M. de (2007), Reproducible and time-dependent modification of serum protein binding in Wistar Kyoto rats., Journal of Pharmacological and Toxicological Methods 56(1): 72-8.
  • Yassen A., Kan J., Olofsen E., Suidgeest E., Dahan A. & Danhof M. (2006), Mechanism based pharmacokinetic/pharmacodynamic modelling of the respiratory depressant effects of buprenorphine in rats, Journal of Pharmacology and Experimental Therapeutics 319: 682-692.
  • Dahan A., Yassen A., Romberg R., Sarton E.Y., Teppema L.J.S.M., Olofsen E. & Danhof M. (2006), Buprenorphine induces ceiling in respiratory depression but not in analgesia, British Journal of Anaesthesia 96(5): 627-632.
  • Bijl H, Yassen A., Olofsen E., Teppema L.J.S.M., Danhof M. & Dahan A. (2006), Full reversal of buprenorphine-induced respiratory depression by the opioid receptor antagonist naloxone, Nederlands Tijdschrift voor Anesthesiologie 19: 58-64.
  • Yassen A., Olofsen E., Bijl H, Romberg R., Sarton E.Y., Danhof M. & Dahan A. (2006), Mechanism-based pharmacokinetic/pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers, Anesthesiology 104: 1232-1242.
  • Dorp E.L. van, Yassen A., Sarton E.Y., Romberg R., Olofsen E., Teppema L.J.S.M., Danhof M. & Dahan A. (2006), Naloxone reversal of buprenorphine-induced respiratory depression, Anesthesiology 105(1): 51-57.
Populariserend
  • Cleton A., Greef H.J.M.M. de, Edelbroek P.M., Voskuyl R.A. & Danhof M. (1998), Pharmacokinetic-pharmacodynamic modeling of the EEG-effect of the GABA uptake inhibitors R- and S-tiagabine. In: Danhof M., Steimer J.L. (Red.) Measurement and kinetics of in vivo drug effects. Advances in simultaneous pharmacokinetic/pharmacodynamic modelling. Leiden: LACDR. 143-145.
  • Cleton A., Graaf P.H. van der, Voskuyl R.A. & Danhof M. (1998), Mechanism-based modelling of the adaptive changes in the pharmacodynamics of midazolan in rats with experimentally induced epilepsy. In: Danhof M., Steimer J.L. (Red.) Measurements and kinetics of in vivo drug effects. Advances in simultaneous pharmacokinetic pharmacodynamic modelling. Leiden: LACDR.
Overig
  • Gotta V., Cools F., van Ammel K., Gallacher D.J., Visser S.A., Sannajust F., Morissette P., Danhof M. & van der Graaf P.H. (2014), Sensitivity of pharmacokinetic-pharmacodynamic analysis for detecting small magnitudes of QTc prolongation in preclinical safety testing, Journal of Pharmacological and Toxicological Methods 72C: 1-10.
  • Stringer F., DeJongh J., Enya K., Koumura E., Danhof M. & Kaku K. (2014), Evaluation of the Long-Term Durability and Glycemic Control of Fasting Plasma Glucose and Glycosylated Hemoglobin for Pioglitazone in Japanese Patients with Type 2 Diabetes, diabetes-technology-and-therapeutics.
  • Mochel J.P., Fink M., Peyrou M., Soubret A., Giraudel J.M. & Danhof M. (2014), Pharmacokinetic/Pharmacodynamic Modeling of Renin-Angiotensin Aldosterone Biomarkers Following Angiotensin-Converting Enzyme (ACE) Inhibition Therapy with Benazepril in Dogs, Pharm Res.
  • Wang C., Allegaert K., Peeters M.Y., Tibboel D., Danhof M. & Knibbe C.A. (2014), The allometric exponent for scaling clearance varies with age: a study on seven propofol datasets ranging from preterm neonates to adults, Br J Clin Pharmacol 77(1): 149-59.
  • Wang C., Allegaert K., Tibboel D., Danhof M., Marel C.D. van der, Mathot R.A. & Knibbe C.A. (2013), Population pharmacokinetics of paracetamol across the human age-range from (pre)term neonates, infants, children to adults., The Journal of Clinical Pharmacology .
  • Cock R.F. de, Allegaert K., Vanhaesebrouck S., Hoon J. de, Verbesselt R., Danhof M. & Knibbe C.A. (2013), Low but Inducible Contribution of Renal Elimination to Clearance of Propylene Glycol in Preterm and Term Neonates, Therapeutic Drug Monitoring.
  • Stringer F., DeJongh J., Scott G. & Danhof M. (2014), A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazar, Br J Clin Pharmacol 54(4): 453-61.
  • Stringer F., Dejongh J., Scott G. & Danhof M. (2013), A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazar, Br J Clin Pharmacol 54(4): 453-61.
  • Piana C., Zhao W., Adkison K., Burger D., Jacqz-Aigrain E., Danhof M. & Della Pasqua O. (2013), Covariate effects and population pharmacokinetics of lamivudine in HIV-infected children, Br J Clin Pharmacol.
  • Piana C., Zhao W., Adkison K., Burger D., Jacqz-Aigrain E., Danhof M. & Della Pasqua O. (2013), A model-based approach for the evaluation of once daily dosing of lamivudine in HIV-infected children, British Journal of Clinical Pharmacology.
  • De Cock R.F., Allegaert K., Sherwin C.M., Nielsen E.I., de Hoog M., van den Anker J.N., Danhof M. & Knibbe C.A. (2014), A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates, Pharmacological Research 31(3): 754-67.
  • Visser S.A., Manolis E., Danhof M. & Kerbusch T. (2013), Modeling and simulation at the interface of nonclinical and early clinical drug development, CPT: Pharmacometrics & Systems Pharmacology .
  • Visser S.A., Manolis E., Danhof M. & Kerbusch T. (2013), Modeling and simulation at the interface of nonclinical and early clinical drug development, CPT: Pharmacometrics & Systems Pharmacology 2(2).
  • Taneja A., Troconiz I.F., Danhof M. & Della Pasqua O.; neuropathic pain project of the PKPD modelling platform (2013), Semi-mechanistic Modelling of the Analgesic Effect of Gabapentin in the Formalin-Induced Rat Model of Experimental Pain, Pharm Res 31(3): 593-606.
  • Wang C., Allegaert K., Peeters M.Y., Tibboel D., Danhof M. & Knibbe C.A. (2013), The allometric exponent for scaling clearance varies with age: a study on seven propofol datasets ranging from preterm neonates to adults, Br J Clin Pharmacol 77(1): 149-59.
  • Pilla Reddy V., Kozielska M., Johnson M., Mafirakureva N., Vermeulen A., Liu J., Greef R. de, Rujescu D., Groothuis G.M., Danhof M. & Proost J.H. (2013), Population pharmacokinetic-pharmacodynamic modeling of haloperidol in patients with schizophrenia using positive and negative syndrome rating scale , Journal of Clinical Psychopharmacology 33(6): 731-9.
  • Knibbe C.A., Tibboel D., Wildt S.N. de, Hoog M. de, Tjoeng M.M. & Danhof M. (2013), [Individualized dosing guidelines for children], Nederlands Tijdschrift voor Geneeskunde 157(16): A4214.
  • Chain A.S., Sturkenboom M.C., Danhof M. & Della Pasqua O.E. (2013), Establishing in vitro to clinical correlations in the evaluation of cardiovascular safety pharmacology., Drug Discovery Today 10(3): 373-83.
  • Wang C., Sadhavisvam S., Krekels E.H., Dahan A., Tibboel D., Danhof M., Vinks A.A. & Knibbe C.A. (2013), Developmental changes in morphine clearance across the entire paediatric age range are best described by a bodyweight-dependent exponent model , Clinical Drug Investigation 33(7): 523-34.
  • Stringer F., Ploeger B.A., DeJongh J., Scott G., Urquhart R., Karim A. & Danhof M. (2013), Evaluation of the impact of UGT polymorphism on the pharmacokinetics and pharmacodynamics of the novel PPAR agonist sipoglitazar , International Journal of Clinical Pharmacology and Therapeutics 53(3): 256-63.
  • De Cock R.F., Allegaert K., Sherwin C.M., Nielsen E.I., Hoog M. de, Anker J.N. van den, Danhof M. & Knibbe C.A. (2013), A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates, Pharm Res 31(3): 754-67.
  • Taneja A., Nyberg J., Lange E.C. de, Danhof M. & Della Pasqua O. (2012), Application of ED-optimality to screening experiments for analgesic compounds in an experimental model of neuropathic pain, JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 39(6): 673-681.
  • Press R.R., Ploeger B.A., Hartigh J. den, Straaten R.J.H.M. van der, Pelt J. van, Danhof M., De Fijter J.W. & Guchelaar H.J. (2007), Improved dose prediction of tacrolimus in de novo kidney transplant patients with population pharmacokinetic modelling including genetic polymorphisms., Bootcongres 2007. Wetenschappelijke voorjaarsvergadering van de Ned. Transplantatie Vereniging : 63.
  • Press R.R., Ploeger B.A., Hartigh J. den, Bemelman F.J., Homan van der Heide J.J., Danhof M., Guchelaar H.J. & Fijter J.W. de (2007), TDM of Everolimus in Stable Renal Transplant Patients after CNI Withdrawal., Therapeutic Drug Monitoring 29(4): 488-488.
  • Press R.R., Ploeger B.A., Hartigh J. den, Straaten R.J.H.M. van der, Pelt J. van, Danhof M., Fijter J.W. de & Guchelaar H.J. (2007), Dose Prediction of Tacrolimus in de novo Kidney Transplant Patients with Population Pharmacokinetic Modelling Including Genetic Polymorphisms., Therapeutic Drug Monitoring 29(4): 530-530.
  • Press R.R., Ploeger B.A., Hartigh J. den, Straaten R.J.H.M. van der, Pelt J. van, Danhof M., Fijter J.W. de & Guchelaar H.J. (2007), Improved Dose Prediction of Tacrolimus in De Novo Kidney Transplant Patients with Population Pharmacokineetic Modelling Including Genetic Polymorphisms., American Journal of Transplantation 7(suppl.2): 440-440.
  • Press R.R., Hartigh J. den, Cremers S.C.L.M., Danhof M., Fijter J.W. de & Guchelaar H.-J. (2006), Dose dependent drug disposition of tacrolimus, Bootcongres 2006 : 51-51.
  • Press R.R., Ploeger B., Hartigh J. den, Cremers S.C.L.M., Danhof M., Fijter J.W. de & Guchelaar H.-J. (2006), Population pharmacokinetics of ciclosporine in kidney transplant patients, Bootcongres 2006 : 27-27.
  • Danhof M. (1998), Whole animal receptor oriented PK/PD for early acceleration of drug development (Lezing). Wiesbaden, Germany.
  • Danhof M. (1998), Whole animal receptor oriented PK/PD for early acceleration of drug development (Lezing). Zagreb, Croatia.
  • Danhof M. (1998), Whole animal receptor oriented PK/PD for early acceleration of drug development (Lezing). Turnhout, Belgium.
  • Danhof M. (1998), Measurement and kinetics of in vivo drug effects, Summary, conclusions and perspectives (Lezing). Noordwijkerhout, NL.
  • Danhof M. (1998), Whole animal receptor oriented PK/PD as a predicitive tool for clinical trials (Lezing). Stockholm, Sweden.
  • Danhof M. (1998), Whole animal receptor oriented PK/PD for early acceleration of drug development (Lezing). Ann Arbor, USA.
  • Danhof M. (1998), Whole animal receptor oriented PK/PD for early acceleration of drug development (Lezing). McClean, Virginia, USA.

Links

Link naar deze pagina
http://hoogleraren.leidenuniv.nl/id/3453

©2015 Universitaire Bibliotheken Leiden www.bibliotheek.leidenuniv.nl